ClinicalTrials.gg
Not yet recruitingNCT07438795INF-STUMP-PAINUpdated Jun 3, 2026

Post-Amputation Stump Infection as a Predictor of Persistent Residual Limb Pain: A Prospective Cohort Study

An observational study in Residual Limb Pain, Stump Pain and Post-Amputation Pain, sponsored by Ukrainian Society of Regional Anesthesia and Pain Therapy. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Ukrainian Society of Regional Anesthesia and Pain Therapy · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Persistent residual limb pain is common after traumatic amputation and significantly impairs rehabilitation and prosthetic use. Postoperative stump infection may contribute to peripheral nerve sensitization, scar fibrosis, and long-term pain persistence. This prospective cohort study aims to determine whether early post-amputation stump infection independently predicts persistent clinically significant residual limb pain at 3 and 6 months after surgery.

Read the detailed description

Patients undergoing traumatic limb amputation will be enrolled within 4 weeks after surgery and followed for 6 months. Early postoperative stump infection will be recorded using predefined clinical criteria. Pain intensity (Numeric Rating Scale), neuropathic pain screening (DN4), and phantom limb pain will be assessed at baseline, 3 months, and 6 months. Multivariable logistic regression will be used to evaluate whether stump infection is independently associated with persistent residual limb pain, adjusting for amputation level, injury mechanism, revision surgeries, antibiotic exposure, and demographic factors.

02

Conditions studied

  • Residual Limb Pain
  • Stump Pain
  • Post-Amputation Pain
  • Surgical Site Infection
  • Phantom Limb Pain (PLP)

Keywords

  • Traumatic amputation
  • stump infection
  • residual limb pain
  • chronic pain
  • surgical site infection
  • blast injury
  • neuropathic pain
03

In context

Surgical Wound Infection

745 studies on the registry are indexed under Surgical Wound Infection; 151 are open to participants now.

This study's planned enrollment of 150 is below the median of 239 across 135 observational studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

Ukrainian Society of Regional Anesthesia and Pain Therapy is the lead sponsor of 15 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult patients (≥18 years) undergoing traumatic upper or lower limb amputation following blast-related, drone-related, or other high-energy injuries. Participants will be enrolled within 4 weeks after primary amputation surgery and followed prospectively for 6 months. The population represents individuals at risk of developing persistent residual limb pain during the early postoperative and rehabilitation period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Traumatic upper or lower limb amputation
  • Enrollment within 4 weeks after surgery
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Pre-existing chronic pain in the affected limb
  • Severe cognitive impairment
  • Terminal illness limiting follow-up
  • Refusal or inability to complete follow-up assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Stump Infection

    Participants who develop postoperative stump infection within 30 days after amputation, defined by clinical signs of infection requiring antibiotic therapy and/or surgical revision.

06

What researchers measure

Primary outcomes

  1. Persistent Clinically Significant Residual Limb Pain

    Presence of clinically significant residual limb pain defined as Numeric Rating Scale (NRS) ≥4 at rest or during movement at 3 months after amputation.

    Time frame: 3 months

Secondary outcomes

  1. Persistent Residual Limb Pain at 6 Months

    NRS ≥4 at rest or during movement at 6 months after amputation.

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07438795
Lead sponsor
Ukrainian Society of Regional Anesthesia and Pain Therapy
Responsible party
Dmytro Dmytriiev (professor, Ukrainian Society of Regional Anesthesia and Pain Therapy) — Principal investigator
First posted
Feb 27, 2026
Start date
Jun 23, 2026 (estimated)
Primary completion
Jun 23, 2026 (estimated)
Completion
Dec 23, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Dmytro Dmytriiev, PhD.Professor
Contact
mddmytriiev@gmail.com
+380674309449

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion